Colchicine-Binding Site Agent CH-2-77 as a Potent Tubulin Inhibitor Suppressing Triple-Negative Breast Cancer

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies.
• Colchicine-binding site inhibitors (CBSI) targeting tubulin are potential anticancer agents, but none are FDA-approved.
• The efficacy of CH-2-77 against TNBC was previously unknown.

Purpose of the Study:

• To evaluate the anticancer activity of CH-2-77 against triple-negative breast cancer (TNBC) in vitro and in vivo.
• To investigate the mechanisms underlying CH-2-77's effects on TNBC cells.
• To assess the therapeutic potential of CH-2-77 for TNBC treatment.

Main Methods:

• In vitro proliferation assays using paclitaxel-sensitive and resistant TNBC cells.
• Microtubule disruption, cell migration, invasion, and cell-cycle analysis.
• Apoptosis assays and Western blot analysis of apoptosis-related proteins.
• In vivo studies using orthotopic MDA-MB-231 xenografts and metastasis models.

Main Results:

• CH-2-77 demonstrated potent antiproliferative activity against TNBC cells (average IC50 of 3 nmol/L).
• CH-2-77 disrupted microtubule assembly, inhibited migration/invasion, and induced G2-M cell-cycle arrest.
• Apoptosis was induced via the intrinsic pathway in TNBC cells treated with CH-2-77.
• In vivo, CH-2-77 suppressed tumor growth and prevented lung metastasis with acceptable pharmacokinetics and low toxicity.
• CH-2-77's efficacy was comparable to the clinical-stage CBSI CA4P.

Conclusions:

• CH-2-77 is a potent inhibitor of TNBC growth and metastasis.
• CH-2-77 acts by disrupting microtubule dynamics and inducing apoptosis.
• CH-2-77 represents a promising new generation of tubulin inhibitors for TNBC therapy.